Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $1.54
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 3, 26 |
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| May 14, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 9, 26 | Needham | maintain | Buy | Buy |
| Mar 31, 26 | Mizuho | maintain | Outperform | Outperform |
| Mar 27, 26 | Needham | maintain | Buy | Buy |
| Jan 12, 26 | Needham | maintain | Buy | Buy |
| Dec 29, 25 | Needham | maintain | Buy | Buy |
| Dec 12, 25 | Needham | maintain | Buy | Buy |
| Nov 3, 25 | Needham | maintain | Buy | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 34.27 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 16.35 | Oscillator | Buy |
| Williams %R (14) | -89.19 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.10 (Hist -0.01) | Oscillator | Strong Sell |
| Average Directional Index (14) | 27.06 (+DI 15.1 / -DI 31.2) | Trend | Strong Sell |
| EMA 20 | 1.72 | MA | Strong Sell |
| SMA 20 | 1.73 | MA | Strong Sell |
| EMA 50 | 1.83 | MA | Strong Sell |
| SMA 50 | 1.99 | MA | Strong Sell |
| SMA 200 | 1.67 | MA | Strong Sell |
Stock news · updated daily
Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2026 meeting being held November 6-11, 2026 in Orlando, Florida.
Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings. Analyst Recommendations This is a breakdown of
LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to obecabtagene autoleucel (obe-cel) for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN).
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier, as the company expanded treatment-center access and continued its commercial launch in the United States and United Kingdom.
LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026.
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million, from $120 – $135 million Capital base strengthened through five-year, interest-only credit facility with $75 million funded at close Autolus to report Q2 2026 financial results on August 11, 2026 LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -0.21 | -0.15 | Beat 28.6% | $45.69M |
| May 14, 2026 | -0.29 | -0.27 | Beat 6.9% | $26.22M |
| Mar 27, 2026 | -0.26 | -0.34 | Miss -30.8% | $24.29M |
| Nov 12, 2025 | -0.23 | -0.30 | Miss -30.4% | $21.19M |
| Aug 12, 2025 | -0.24 | -0.18 | Beat 25.0% | $20.92M |
| May 8, 2025 | -0.24 | -0.26 | Miss -8.3% | $8.98M |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | AUTL | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.5x | -2.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -2.0x | EPS est. -0.78 | Elevated |
| Price / Book | 5.5x | 3.2x | Elevated |
| Price / Sales | 3.5x | 200.7x | Discount |
| EV / EBITDA | -1.5x | -2.1x | Discount |
| Return on equity | -178.6% | — | Weak |
| Gross margin | 15.7% | -204.3% | Below hist. |
| Debt / Equity | 1.12 | 0.57 | Moderate |
| Piotroski / Altman Z | 3/9 | Z -4.31 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 1, 26 | Piccina Cintia | officer: U.S. CCO & Country Gen Manager | M-Exempt | 20,000 | — |
| Sep 1, 26 | Piccina Cintia | officer: U.S. CCO & Country Gen Manager | M-Exempt | 20,000 @ $2.35 | $47.00K |
| Sep 2, 26 | Piccina Cintia | officer: U.S. CCO & Country Gen Manager | S-Sale | 6,713 @ $2.34 | $15.68K |
| Jun 29, 26 | Young William D | director | A-Award | 47,500 @ $1.61 | $76.47K |
| Jun 29, 26 | Young William D | director | A-Award | 31,667 | — |
| Jun 29, 26 | Rao Madduri Ravin | director | A-Award | 47,500 @ $1.61 | $76.47K |
| Jun 29, 26 | Rao Madduri Ravin | director | A-Award | 31,667 | — |
| Jun 29, 26 | Richardson Ryan | director | A-Award | 47,500 @ $1.61 | $76.47K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| EFFECT | Sep 22, 2026 | 2026-09-23 00:15:19 | View |
| 424B3 | Sep 22, 2026 | 2026-09-22 16:51:01 | View |
| DEL AM | Sep 15, 2026 | 2026-09-15 16:22:31 | View |
| S-3 | Sep 14, 2026 | 2026-09-11 20:48:29 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:36:38 | View |
| SC 13D/A | Aug 28, 2026 | 2026-08-28 21:08:04 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 10:01:46 | View |
| 10-Q | Aug 11, 2026 | 2026-08-11 16:13:51 | View |
| 8-K | Aug 11, 2026 | 2026-08-11 07:33:42 | View |
| 8-K | Aug 3, 2026 | 2026-08-03 08:11:28 | View |
Proxy statement (DEF 14A) disclosures